Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

Perioperative durvalumab continues to show clinical benefit in patients with resectable stage IIA to IIIB NSCLC
Дата публикации: 17-09-2026 07:09:00

Findings from a second planned interim analysis of the AEGEAN study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Perioperative durvalumab plus FLOT improves OS in patients with resectable gastric or GEJ adenocarcinoma09.2215-09-2026
2Tebentafusp continues to provide long-term OS benefit in previously untreated patients with unresectable or metastatic uveal melanoma014.9321-09-2026
3Daraxonrasib shows antitumour activity in patients with previously treated metastatic RAS-mutated NSCLC015.8810-09-2026
4Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions0523-06-2026
5Comprehensive genomic profiling with subsequent molecularly guided therapy improves outcomes over platinum-based chemotherapy in previously untreated, unfavourable CUP016.4122-09-2026
6DDW: Sanofi and Regeneron’s DUPIXENT® demonstrates improved esophageal function in eosinophilic esophagitis phase 4 study016.6705-05-2026
7Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma0509-07-2026
8Projected Benefit of Bilateral Salpingo-Oophorectomy by Age in BRCA Carriers011.3423-09-2026
9Azacitidine-venetoclax prolongs EFS over induction chemotherapy among induction-eligible patients with AML022.514-09-2026
10Individualized Stereotactic Ablative Radiotherapy for Lung Tumors06.601-11-2023

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 9.27. Источник: www.esmo.org.